Background: Nucleoside-sparing combination antiretroviral therapy (cART) regimens might be an attractive therapeutic option for HIV type-1 (HIV-1)-infected patients; however, the pharmacokinetic profiles of such regimens are frequently unknown. Methods: Fourteen HIV-1-infected patients (age 21-55 years, 64% male) on stable cART with plasma HIV RNA <50 copies/ml entered this Phase I pharmacokinetic study. In period 1, patients received tenofovir/emtricitabine/ darunavir/ritonavir (300/200/800/100 mg) all once daily. During period 2, raltegravir 400 mg twice daily was added to the regimen and in period 3 tenofovir/emtricitabine was discontinued. At steady state, intensive pharmacokinetic sampling was undertaken. Differences in the geometric mean ratio (GMR) for pharmacokinetic parameters between periods 2 versus 1 and period 3 versus 1 were assessed for darunavir and ritonavir (period 3 versus 2 for raltegravir). Combination antiretroviral therapy (cART) regimens that can achieve sustained virological suppression, while minimizing treatment-related toxicities, remain paramount to the successful management of chronic HIV type-1 (HIV-1) infection. Nucleoside reverse transcriptase inhibitors (NRTIs) have been prescribed widely over the past 20 years, and remain an integral component of cART [1] [2] [3] . However, this drug class is associated with side effects, including mitochondrial toxicities, changes to body shape and lipids, increased cardiovascular risk, and renal dysfunction [4] [5] [6] . For these reasons NRTI-sparing regimens are desirable, yet when periodically evaluated in clinical trials they have failed to demonstrate justification for widespread implementation [7, 8] .
Background: Nucleoside-sparing combination antiretroviral therapy (cART) regimens might be an attractive therapeutic option for HIV type-1 (HIV-1)-infected patients; however, the pharmacokinetic profiles of such regimens are frequently unknown. Methods: Fourteen HIV-1-infected patients (age 21-55 years, 64% male) on stable cART with plasma HIV RNA <50 copies/ml entered this Phase I pharmacokinetic study. In period 1, patients received tenofovir/emtricitabine/ darunavir/ritonavir (300/200/800/100 mg) all once daily. During period 2, raltegravir 400 mg twice daily was added to the regimen and in period 3 tenofovir/emtricitabine was discontinued. At steady state, intensive pharmacokinetic sampling was undertaken. Differences in the geometric mean ratio (GMR) for pharmacokinetic parameters between periods 2 versus 1 and period 3 versus 1 were assessed for darunavir and ritonavir (period 3 versus 2 for raltegravir). No statistically significant changes were observed in ritonavir or raltegravir pharmacokinetic parameters. Darunavir C trough <550 ng/ml (the minimum effective concentration for protease-resistant HIV viral isolates) was observed in four patients during period 3 only. No clinically significant safety concerns were reported. Conclusions: Darunavir C trough is reduced by 36% when administered without tenofovir/emtricitabine in HIV-1 -infected patients. This interaction might be of clinical significance in the management of individuals with protease-resistant HIV viral isolates.
Combination antiretroviral therapy (cART) regimens that can achieve sustained virological suppression, while minimizing treatment-related toxicities, remain paramount to the successful management of chronic HIV type-1 (HIV-1) infection. Nucleoside reverse transcriptase inhibitors (NRTIs) have been prescribed widely over the past 20 years, and remain an integral component of cART [1] [2] [3] . However, this drug class is associated with side effects, including mitochondrial toxicities, changes to body shape and lipids, increased cardiovascular risk, and renal dysfunction [4] [5] [6] . For these reasons NRTI-sparing regimens are desirable, yet when periodically evaluated in clinical trials they have failed to demonstrate justification for widespread implementation [7, 8] .
Newly licensed antiretroviral agents with different mechanisms of action are now available, thereby justifying the re-investigation of novel NRTI-sparing cART. Antiretroviral regimens containing the integrase inhibitor raltegravir and the protease inhibitor darunavir boosted with ritonavir, together with NRTI backbones, have demonstrated potent antiviral activity in HIV-1-infected patients previously naive to therapy [9, 10] Original article Introduction and in highly therapy-experienced patients [11, 12] . Combining two new active agents, such as darunavir/ ritonavir and raltegravir, might thus provide a potent, nucleoside-sparing regimen.
Prior to assessing new antiretroviral agents as part of a novel therapeutic approach in clinical trials, the pharmacokinetic and short-term safety profiles require exploration. As the HIV-1 protease inhibitors are metabolized via cytochrome P450 (CYP450), drugdrug interactions are frequently observed. Raltegravir is primarily metabolized by glucuronidation and has no known inhibitory or inductive potential against the major CYP450 enzymes, which make this compound less likely to be prone to such drug-drug interactions. Despite this, significant pharmacokinetic interactions with raltegravir have been reported [13, 14] .
The aim of this study was to evaluate the pharmacokinetic profile of darunavir/ritonavir when dosed once daily with and without raltegravir and with and without tenofovir/emtricitabine in HIV-1-infected patients receiving stable antiretroviral therapy.
Methods

Study design and patient selection
This open-label, Phase I prospective study evaluated the pharmacokinetic and tolerability profile of oncedaily darunavir/ritonavir when administered with tenofovir/emtricitabine alone (period 1), with tenofovir/ emtricitabine plus raltegravir (period 2) and with raltegravir alone (period 3) in HIV-1-infected patients.
The study was conducted at Imperial College Healthcare Trust at St Mary's Hospital, London, UK, between November 2008 and January 2009. Adult patients on stable antiretroviral therapy comprising tenofovir/ emtricitabine and a ritonavir-boosted protease inhibitor were eligible to participate. Exclusion criteria included genotypic evidence of HIV protease inhibitor resistance, pregnancy, active hepatitis B or C infection, alcohol abuse or drug dependence (positive drug screen at any study visit), significant comorbidities, current opportunistic infections, prohibited concomitant medication (including illegal drugs, systemic chemotherapeutic agents, immunosuppressive or immunomodulatory drugs, clarithromycin, rifamycins, doxycycline, isoniazid, all herbal products, anticonvulsants, erectile dysfunction therapies, oral contraceptives, medications dependent upon CYP3A or CYP2C19 for clearance, medications that might interfere with darunavir and or ritonavir metabolism [such as warfarin and theophylline], and all other investigational drugs), body weight <60 kg or body mass index (BMI) >30. All patients had a plasma HIV RNA <50 copies/ml (Quantiplex assay™; Bayer, Emeryville, CA, USA) for >3 months prior to study entry. This study was registered on the European Clinical Trials Database (EudraCT number 2008-003239-19) and local ethical approval was attained prior to recruiting participants.
Study treatments
During period 1 (days 1-10), all participants switched antiretroviral therapy to tenofovir/ emtricitabine/ darunavir/ritonavir (300/200/800/100 mg) once daily. In period 2 (days [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , participants received tenofovir/emtricitabine/darunavir/ritonavir (300/200/800/100 mg) once daily plus raltegravir (400 mg) twice daily. In period 3 (days 21-30), tenofovir/emtricitabine was discontinued and participants were maintained on darunavir/ritonavir (800/100 mg) once daily plus raltegravir (400 mg) twice daily.
Pharmacokinetic sampling
Dosing was witnessed and adherence assessed using simple questions from a validated screening tool [15] on days 1, 5, 10, 15, 20, 25 and 30. Intensive pharmacokinetic sampling was performed only after reaching steady state (elapsed time receiving drug greater than six elimination half-lives) on days 10, 20 and 30, thereby minimizing any pharmacokinetic effect from components of prior drug regimens. A standardized breakfast containing 20 g fat (600 kcal) was administered 15 min before morning dosing and drug intake witnessed. Plasma samples for pharmacokinetic analysis were taken at 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h post-dosing. Haematological and biochemical blood tests, urine pregnancy test (where applicable), urine drug screen, CD4 + T-cell subsets and plasma HIV RNA were assayed at each study visit. Plasma concentrations of darunavir, ritonavir and raltegravir were determined using a validated HPLC tandem mass spectrometry method in a laboratory that participates in an external quality control programme twice yearly (Dutch KKGT [Stichting Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie]) [16] . The lower limit of quantification (defined as the lowest concentration of standard used to determine each analyte in this study) was 33 ng/ml for ritonavir, 109 ng/ml for darunavir and 5 ng/ml for raltegravir. Intra-and interassay variability was <10% for each analyte.
Statistical analysis
The pharmacokinetic parameters calculated for darunavir, ritonavir and raltegravir were trough plasma concentration (C trough ), defined as the concentration at 24 or 12 h after the observed dose, the maximum observed plasma concentration (C max ), the area under the plasma concentration-time curve from 0 to 24 h (AUC 0-24h ) or 0 to 12 h (AUC 0-12h ) and the elimination half-life (t 1/2 ). When a drug concentration was below the lower limit of quantification (LLQ), the value used for analysis was the LLQ/2. Area under the plasma concentration-time curve (AUC τ ) and t 1/2 were calculated using non-compartmental modelling techniques (WinNolin; Pharsight Corporation, Mountain View, CA, USA).
All statistical calculations were performed using SPSS software (version 16.0; SPSS Inc., Chicago, IL, USA). Geometric mean ratios (GMR) and 95% confidence intervals (CIs) were used to evaluate withinpatient changes for pharmacokinetic parameters from periods 1 to 2 and 1 to 3 (darunavir, ritonavir) and periods 2 to 3 (raltegravir only). The 95% CIs were calculated using logarithms of the individual geometric mean values with calculated values then expressed as linear values. The changes in pharmacokinetic parameters were considered significant when 95% CIs did not exceed 1. Interpatient variability in pharmacokinetic parameters was expressed as a coefficient of variation (CV; [standard deviation/mean] ×100).
Associations between antiretroviral pharmacokinetic parameters (log 10 transformed) and patient characteristics (age, gender, ethnicity, BMI, smoking status and plasma CD4 + T-cell count) were investigated using linear regression modelling. Confidence intervals were then expressed as linear values. All univariate associations with a P-value <0.1 were included in multivariate analyses and values <0.05 were considered statistically significant.
Results
Patient characteristics and drug tolerability
Of the 20 patients screened, 14 enrolled and completed study procedures (9 male, 5 female; mean age 40 years, range 21-55). Patient characteristics are shown in Table 1 . Study medications were well-tolerated throughout and there were no discontinuations. No grade 3 or 4 adverse events or laboratory abnormalities occurred. Five patients experienced a single grade 2 adverse event, of which only one (fatigue) was classified as possibly related to medication. In one patient an HIV RNA level of 142 copies/ml was detected during period 2, but this decreased to <50 copies/ml when the measurement was repeated. All other HIV RNA analyses during the study period were <50 copies/ml. All patients reported 100% adherence to therapy and paracetamol was the only additional medication required.
Pharmacokinetic parameters over study periods
Pharmacokinetic parameters for darunavir, ritonavir and raltegravir during all study periods are shown in Table 2 . No significant differences in parameters were observed between period 1 and period 2. A significant reduction in darunavir C trough was observed during period 3 compared with period 1 (GMR 0.64 ng/ml, 95% CI 0.44-0.93). This was associated with a decreased darunavir t 1/2 (GMR 0.69 h, 95% CI 0.46-1.05), but no significant change in AUC 0-24h (GMR 0.92 ng h/ml, 95% CI 0.78-1.08) was observed. Darunavir C trough concentrations of individual patients between periods 1 and 3 are displayed in Figure 1 . No statistically significant changes in the plasma exposure of ritonavir or raltegravir were observed throughout the study. High variability in raltegravir plasma exposure was observed throughout (AUC CV 80% and 69%, periods 2 and 3, respectively).
Factors associated with darunavir plasma exposure
No associations were observed between darunavir pharmacokinetic parameters and gender, ethnicity, plasma CD4 + T-cell count or BMI (P>0.33 for all cases). Interestingly, throughout the study, older age was significantly associated with an increase in darunavir AUC 24h exposure (P=0.002; 95% CI 1,377-4,121) and plasma C max concentration (P=0.013; 95% CI 48-262).
Discussion
Nucleoside-sparing antiretroviral regimens are a desirable treatment option for HIV-1-infected individuals, yet clinical trials evaluating such strategies have reported disappointing results to date [7, 8, 17] . In this pharmacokinetic study of HIV-infected patients, we observed no short-term safety or potency concerns upon switching antiretroviral therapy to a novel, nucleoside-sparing regimen comprising solely of two active agents (ritonavir-boosted darunavir and raltegravir). Interesting observations were made; most importantly, a reduction in darunavir plasma exposure during the nucleoside-sparing phase of the study, resulting in almost one-third of individuals (n=4/14) displaying a C trough below the suggested darunavir minimum effective concentration (MEC) for drugresistant HIV isolates (550 ng/ml) [18] . Levels did not fall below the MEC for wild-type HIV isolates (55 ng/ ml) at any time point. The underlying mechanisms of the pharmacokinetic interaction observed upon cessation of tenofovir/emtricitabine are unclear. Emtricitabine has not been reported to exert a significant pharmacokinetic influence on the plasma exposure of other antiretroviral agents [19, 20] , whereas such interactions have been reported with tenofovir. Reduced atazanavir exposure, when coadministered with tenofovir, has been described, but this can be overcome with ritonavir boosting [21] . Increased plasma exposure of saquinavir, when given with Table 2 . Pharmacokinetic parameters for darunavir, ritonavir and raltegravir during study periods 1, 2 and 3 AUC, area under the plasma concentration-time curve; CI, confidence interval; C max , maximum observed plasma concentration; C trough , trough plasma concentration; CV, coefficient of variation ([standard deviation/mean]×100); GM, geometric mean; GMR, geometric mean ratio; t 1/2 , elimination half life. tenofovir, has also been reported, although again this is not considered clinically relevant [22] . Similarly, in a healthy volunteer study, increases in darunavir plasma C trough , C max and AUC 12h of 24%, 16% and 21%, respectively, were observed following addition of tenofovir 300 mg once daily without any additional toxicities [23] . Notably this study assessed darunavir at lower doses (300/100 mg twice daily) than are currently used in clinical practice. The pharmacological influence of tenofovir on the metabolism of the HIV-1 protease inhibitors is unexpected because tenofovir neither induces nor inhibits the major CYP450 enzymes and is eliminated largely unchanged by the kidney [24] . Furthermore, in vitro, tenofovir inhibits P-glycoprotein (a transmembrane transporter) less than other members of the NRTI class [25] . It is possible that tenofovir alters gastric pH levels, thereby reducing absorption of drugs with pH-dependent solubility; this is a similar mechanism of interaction to that observed between protease inhibitors and proton-pump inhibitors [26] .
Interestingly, we observed a significant association between older age and greater darunavir plasma exposure (P=0.03 and P=0.024 for AUC and C max , respectively, in period 3). Mean age in our cohort was 40 years. Observed mean (±sd) darunavir AUC 24h in period 3 was greater than twofold higher (99,745 ±33,989 versus 47,639 ±18,245 ng • h/ml) in patients above and below 40 years of age. To our knowledge, this relationship has not been previously reported. We postulate it might reflect the reduction in hepatic metabolism reported with increasing age [27] and, whilst increased darunavir plasma exposure might increase the 'genetic barrier' for selection of resistant HIV-1 viral strains, it could also be associated with increased toxicity requiring heightened clinical vigilance.
In summary, the nucleoside-sparing antiretroviral regimen evaluated in this study might be suitable for assessment in future clinical trials; however, caution is required, particularly in patients with resistant HIV viral species. Our study recruited otherwise healthy, HIV-infected patients on stable antiretroviral therapy; therefore, the observations made might not be transferable to resource-poor settings, where nutritional status and ethnicity might have additional effects on drug metabolism [28] [29] [30] . Current antiretroviral treatment guidelines recommend the use of, where possible, three active drugs [1] [2] [3] . Previous studies assessing the use of antiretroviral regimens containing only two active drugs (such as double-boosted protease inhibitors) have had inconsistent results in different populations [31] [32] [33] . Results of clinical trials evaluating novel two-drug regimens are not currently available and therefore, although timely given that new classes of antiretroviral drugs are now available, such regimens cannot currently be recommended for routine clinical use. Further work to elucidate the mechanism underlying this important drug-drug interaction is required.
